Pluvicto and lutathera injection

Ended Awarded Last action

Contract number
HT941026FE027
Awardee
Awarding agency
Obligated
$205,766

Award facts

Contract value 100% obligated
$205,765.56 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
NAICS code
325412 Pharmaceutical Preparation Manufacturing
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Not Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
East Hanover, NJ 07936, USA

Award details come from SAM.gov/FPDS.

About this award

The Defense Health Agency issued a BPA call to Novartis Pharmaceuticals Corporation on February 11, 2026, for Pluvicto and Lutathera injection with a ceiling value of $205,765.56 under a single-award Indefinite Delivery Contract with the Defense Health Agency. The parent contract, awarded October 1, 2024, has a ceiling of $26,095,049.21 and extends through September 30, 2029, for procurement of two cancer therapy drugs—Lutathera and Pluvicto—utilizing firm fixed-price line items. Work is performed at East Hanover, New Jersey. The call is due to complete by September 30, 2026. No set-aside was used.

Quick answers

Who was awarded contract HT941026FE027?

HT941026FE027 was awarded to Novartis Pharmaceuticals Corporation by Defense Health Agency (Department of Defense) on February 11, 2026.

How much is contract HT941026FE027 worth?

The government has obligated $205,766 on HT941026FE027.

Is contract HT941026FE027 an order under another contract?

Yes. HT941026FE027 is a BPA call under HT941026AE002, a blanket purchase agreement.

Was contract HT941026FE027 competed?

The extent of competition for HT941026FE027 was not competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award